Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-18-296460
Filing Date
2018-10-10
Accepted
2018-10-10 09:07:35
Documents
6
Effectiveness Date
2018-10-10

Document Format Files

Seq Description Document Type Size
1 DEFA14A d617939ddefa14a.htm DEFA14A 39821
2 GRAPHIC g6179393a.jpg GRAPHIC 2805
3 GRAPHIC g617939g33k85.jpg GRAPHIC 4335
4 GRAPHIC g617939g34o52.jpg GRAPHIC 4338
5 GRAPHIC g617939g67w93.jpg GRAPHIC 4329
6 GRAPHIC g617939g75q50.jpg GRAPHIC 4238
  Complete submission text file 0001193125-18-296460.txt   68726
Mailing Address 320 WAKARA WAY SALT LAKE CITY UT 84108
Business Address 320 WAKARA WAY SALT LAKE CITY UT 84108 801-584-3600
MYRIAD GENETICS INC (Filer) CIK: 0000899923 (see all company filings)

EIN.: 870494517 | State of Incorp.: DE | Fiscal Year End: 0630
Type: DEFA14A | Act: 34 | File No.: 000-26642 | Film No.: 181114976
SIC: 2835 In Vitro & In Vivo Diagnostic Substances